Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447337 | 0.85 | GRM2 (0.35) | GRM2PIM1NNMTKDM4EMAPT | |
| SCHEMBL4484391 | 0.74 | GRM2 (0.35) | GRM2PIM1NNMTPTPN1 | |
| SCHEMBL14955110 | 0.71 | PIM1 (0.38) | GRM2PIM1NNMTMAPTRAB9A | |
| SCHEMBL3050408 | 0.69 | PIM1 (0.33) | GRM2PIM1NNMTKDM4EIKBKB | |
| SCHEMBL31507586 | 0.69 | PIM1 (0.41) | GRM2PIM1NNMTKDM4ETDP1 | |
| SCHEMBL26684509 | 0.69 | PIM1 (0.41) | GRM2PIM1NNMTKDM4ETDP1 | |
| SCHEMBL11973236 | 0.68 | PIM1 (0.38) | GRM2PIM1NNMTIKBKB | |
| SCHEMBL4473023 | 0.68 | NNMT (0.41) | GRM2PIM1NNMTKDM4EIKBKB | |
| SCHEMBL153746 | 0.65 | RAB9A (0.41) | GRM2PIM1NNMTKDM4EMAPT | |
| SCHEMBL4473874 | 0.65 | PIM1 (0.41) | GRM2PIM1NNMTDGAT1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | KANE JOHN L JR | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254894-A1 | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation | MKI67, VEGFA, KDR | GRM2 4776/4885PIM1 971/4885NNMT 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.